Wedbush Reaffirms Outperform Rating for Telix Pharmaceuticals (NASDAQ:TLX)

Key Points

• Wedbush reaffirmed an "Outperform" rating on Telix with a $22 price target, implying roughly a 108.7% upside from the prior close.
• Analyst coverage is mixed but skewed positive — consensus is a "Moderate Buy" with an average price target of $21.13 (one Strong Buy, six Buy, one Hold, one Sell).
• Telix recently missed expectations, reporting (‑$0.01) EPS vs. $0.05 expected and revenue of $206.7M vs. $421.5M expected, while the stock trades around $10.54 (1‑year high $20, low $6.28).

Telix Pharmaceuticals (NASDAQ:TLX - Get Free Report)'s stock had its "outperform" rating reissued by Wedbush in a research note issued on Monday,Benzinga reports. They presently have a $22.00 price objective on the stock. Wedbush's price objective would suggest a potential upside of 108.73% from the stock's previous close.

A number of other research analysts also recently commented on TLX. Wall Street Zen upgraded Telix Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday. HC Wainwright restated a "buy" rating and issued a $20.00 target price on shares of Telix Pharmaceuticals in a research note on Monday. Weiss Ratings restated a "sell (d)" rating on shares of Telix Pharmaceuticals in a research note on Wednesday, January 21st. Royal Bank Of Canada upgraded Telix Pharmaceuticals from a "hold" rating to a "moderate buy" rating in a research note on Monday, January 19th. Finally, Citigroup boosted their target price on Telix Pharmaceuticals from $22.00 to $22.50 and gave the company a "buy" rating in a research note on Tuesday, February 24th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, Telix Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $21.13.

Telix Pharmaceuticals Price Performance

NASDAQ TLX opened at $10.54 on Monday. Telix Pharmaceuticals has a 1-year low of $6.28 and a 1-year high of $20.00. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08. The firm's fifty day simple moving average is $7.90 and its 200-day simple moving average is $8.71.

Telix Pharmaceuticals (NASDAQ:TLX - Get Free Report) last issued its earnings results on Friday, February 20th. The company reported ($0.01) EPS for the quarter, missing analysts' consensus estimates of $0.05 by ($0.06). The business had revenue of $206.72 million during the quarter, compared to analysts' expectations of $421.50 million. Analysts expect that Telix Pharmaceuticals will post 0.24 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Telix Pharmaceuticals

A number of large investors have recently bought and sold shares of TLX. Rhumbline Advisers boosted its holdings in Telix Pharmaceuticals by 117.3% in the third quarter. Rhumbline Advisers now owns 2,579 shares of the company's stock worth $25,000 after purchasing an additional 1,392 shares in the last quarter. XTX Topco Ltd bought a new stake in Telix Pharmaceuticals in the fourth quarter worth $89,000. OLD Mission Capital LLC bought a new stake in Telix Pharmaceuticals in the fourth quarter worth $111,000. Vident Advisory LLC acquired a new position in Telix Pharmaceuticals during the 4th quarter worth $204,000. Finally, IHT Wealth Management LLC acquired a new position in Telix Pharmaceuticals during the 2nd quarter worth $213,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals NASDAQ: TLX is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.